Publications by authors named "A Murias"

Studying the genetics of phenotypic convergence can yield important insights into adaptive evolution. Here, we conducted a comparative genomic study of four lineages (species and subspecies) of anadromous shad () that have independently evolved life cycles entirely completed in freshwater. Three naturally diverged (.

View Article and Find Full Text PDF

Ankyloglossia, commonly known as tongue-tie, is the most common disorder of tongue morphology characterized by aberrant attachment of the lingual frenum. This study aimed to provide a comprehensive literature review and evaluate the effectiveness of various laser wavelengths in the surgical treatment of patients with ankyloglossia. An electronic screening of PubMed and the Cochrane Central Register of Controlled Trials (CENTRAL) databases was conducted on 8 November 2021.

View Article and Find Full Text PDF

Nicotine exerts its addictive influence through the meso-cortico-limbic reward system, where the striatum is essential. Nicotine addiction involves different neurotransmitters, nitric oxide (NO) being especially important, since it triggers the release of the others by positive feedback. In the nervous system, NO is mainly produced by nitric oxide synthase 1 (NOS1).

View Article and Find Full Text PDF
Article Synopsis
  • The chemistry and surface structure of dental and orthopedic implants are crucial for effective tissue integration.
  • Titanium implants modified with calcium ions show improved interface properties, preventing unwanted elements from affecting the surface.
  • In studies, these calcium-modified implants enhanced cell growth and bone contact in animal models, indicating their potential to improve implant integration in clinical settings.
View Article and Find Full Text PDF

Background: Efficacy and safety data for combining bevacizumab, gemcitabine, and paclitaxel for locally advanced/metastatic breast cancer are limited.

Patients And Methods: AVALUZ trial evaluates the combination of bevacizumab 10 mg/kg, gemcitabine 2,000 mg/m(2) plus paclitaxel 150 mg/m(2), on days 1 and 15 of each 28-day course in previously untreated HER-2 negative patients.

Results: Median progression-free survival (PES): 12.

View Article and Find Full Text PDF